Bodhi Tree Biotechnology Inc. income statement BDTB

In fiscal 2025, which ended Sep 30, 2025, Bodhi Tree Biotechnology Inc. reported revenue of $17,000. It recorded a net loss of $149,666. The operating loss came to $147,618, an operating margin of -868.3%. Diluted earnings per share were -$0.01. Over the twelve months ended Jun 30, 2026, revenue was $37,000 and the net loss was $116,025.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Sep 30, 2025
Revenue
0
0
Selling, general and administrative
0
0
Operating income
-0
-0
Other non-operating income (expense)
0
0
Pretax income
-0
-0
Income tax
0
0
Net income
-0
-0
Basic EPS
-0.00
-0.01
Diluted EPS
-0.00
-0.01
Weighted average shares, basic
25
25
Weighted average shares, diluted
25
25
Margins
Operating margin
-310.18%
-868.34%
Pretax margin
-310.17%
-868.33%
Profit margin
-313.58%
-880.39%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Services-Management Consulting Services (SIC 8742)
Listed as
BDTB (OTC)
Fiscal year ends
September 30
Incorporated in
DE
Headquarters
Danville, CA
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2041531

Other Services-Management Consulting Services companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.